[18-F]CETO([18-F]CETO) - 在研适应症：醛固酮增多症_专利_临床

概要

基本信息

药物类型

化学药、诊断用放射药物

别名-

靶点-

作用机制

PET imaging(正电子发射断层成像术增强剂)

治疗领域

内分泌与代谢疾病

在研适应症

醛固酮增多症

非在研适应症

ACTH非依赖性大结节样肾上腺增生症肾上腺皮质腺瘤肾上腺皮质癌

原研机构

University of Calgary

在研机构

University of Calgary

非在研机构

University of Uppsala

University of Cambridge

最高研发阶段临床2期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

3

项与 [18-F]CETO 相关的临床试验

NCT05472493 / Recruiting临床2期

Nuclear Imaging for Subtype Diagnosis of Primary Aldosteronism

This study is to evaluate the accuracy of a novel radiopharmaceutical tracer, para-chloro-2-[18F]fluoroethyl etomidate (CETO), used with positron emission tomography (PET) and computed tomography (CT), as a way to subtype unilateral vs. bilateral forms of Primary Aldosteronism, compared to AVS as a reference gold standard.

开始日期2023-01-01

申办/合作机构

University of Calgary

NCT04529018 / Unknown statusN/A

A Phase 1 Clinical Trial Evaluating the Safety and Efficacy of up to Two Administrations of the Adrenal PET Tracer [18F]CETO in Healthy Volunteers and Patients With Primary Aldosteronism

The study is a Phase 1, single-centre, open label, micro-dosing study. The aim is to investigate an innovative new tracer, [18F]CETO, as a potential alternative to adrenal vein sampling for the lateralisation of primary aldosteronism (PA).

开始日期2020-08-03

申办/合作机构

University of Cambridge

[+1]

NCT05361083 / Completed早期临床1期

Studies of 18F-CETO as a Tracer for Adrenal PET Diagnostics

Purpose of this clinical phase 1 trial was to determine if para-chloro-2-[18F]fluoroethyletomidate positron emission computed tomography ([18F]CETO-positron emission computed tomography(PET)/computed tomography(CT)) can be used in diagnostics of adrenal tumors and if the biochemical/pharmacological states conditions in humans with various illnesses, compared to healthy humans, such as the radio tracer is suitable?

开始日期2019-09-01

申办/合作机构

University of Uppsala

[+1]

100 项与 [18-F]CETO 相关的临床结果

登录后查看更多信息

100 项与 [18-F]CETO 相关的转化医学

登录后查看更多信息

100 项与 [18-F]CETO 相关的专利（医药）

登录后查看更多信息

100 项与 [18-F]CETO 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
醛固酮增多症	临床2期	加拿大	University of Calgary	2023-01-01
ACTH非依赖性大结节样肾上腺增生症	临床1期	瑞典	University of Uppsala	2019-09-01
肾上腺皮质腺瘤	临床1期	瑞典	University of Uppsala	2019-09-01
肾上腺皮质癌	临床1期	瑞典	University of Uppsala	2019-09-01